Brickell Biotech
- Company typePrivate
- Founded2009
- HeadquartersMiami, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Brickell Biotech firmographics
Firmographics- Name
- Brickell Biotech
- Website
- https://brickellbio.com
- Company type
- Private
- Founded year
- 2009
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Brickell Biotech industry classification
Industry- Product category
- Dermatology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
Keywords
Where Brickell Biotech is headquartered
LocationHeadquarters
- HQ city
- Miami
- HQ country
- United States
- HQ region
- North America
Markets served
Brickell Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Brickell Biotech product offering
Product offeringCore offering
Brickell Biotech is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of prescription drug therapies for the treatment of skin diseases, including hyperhidrosis (excessive sweating). The company develops proprietary topical small-molecule therapeutics targeting dermatological conditions and has expanded its pipeline through corporate acquisitions such as Vical.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug therapies for skin diseases
Companies that use Brickell Biotech
Customer profileIdeal customer profiles1 record
Brickell Biotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Brickell Biotech partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Brickell Biotech competitors and assessment
Company assessmentEmerging players
- AnaptysBio: AnaptysBio is a clinical-stage biotechnology company with a pipeline that includes dermatology indications (such as atopic dermatitis), making it a relevant emerging comparator in dermatology drug development.
- Incyte Corporation: Incyte has built a meaningful dermatology franchise (e.g., opzelura) and competes in adjacent inflammatory skin disease indications, providing a relevant emerging competitive reference for Brickell.
Others
- Hologic: Hologic participates in the broader women's health and dermatology/energy-based aesthetics markets referenced alongside Brickell's competitive set, with partial thematic overlap in dermatology devices/aesthetics.
Direct peers
- Revance Therapeutics: Revance is a direct competitor in the hyperhidrosis and broader dermatology/aesthetics space, specifically developing therapeutic solutions that overlap with Brickell's focus on skin disease drug therapies.
- Arcutis Biotherapeutics: Arcutis is a clinical and commercial-stage dermatology specialty pharmaceutical company developing topical treatments for skin conditions, sharing Brickell's therapeutic area and small-cap public profile.
- Dermavant Sciences: Dermavant is a dermatology-focused specialty pharma developing innovative topical therapies for skin diseases, directly comparable to Brickell's dermatology drug development focus.
- Verrica Pharmaceuticals: Verrica is a dermatology-focused specialty pharma developing treatments for skin diseases, including commercial and clinical-stage assets, making it a closely comparable peer in size and scope.
- Sol-Gel Technologies: Sol-Gel is a dermatology specialty pharmaceutical company developing topical branded generics and innovative therapies for skin diseases, comparable in scale and therapeutic focus to Brickell.
Broad incumbents
- AbbVie: AbbVie is a broad incumbent in the hyperhidrosis space through Botox and Allergan Aesthetics, providing a well-funded competitive backdrop against which Brickell's small specialty pharma strategy must execute.
- Galderma: Galderma is one of the world's largest dermatology-focused pharmaceutical companies, offering prescription, aesthetic, and consumer skin health products — a broad incumbent with significant overlap to Brickell's specialty.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Brickell Biotech social profiles
Digital presenceBrickell Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brickell Biotech leadership team
Management profileNumber of profiles
Profiles12 records
Brickell Biotech funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brickell Biotech M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brickell Biotech
What does Brickell Biotech do?
Brickell Biotech is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of prescription drug therapies for the treatment of skin diseases, including hyperhidrosis (excessive sweating). The company develops proprietary topical small-molecule therapeutics targeting dermatological conditions and has expanded its pipeline through corporate acquisitions such as Vical.
When was Brickell Biotech founded?
Brickell Biotech was founded in 2009. It employs 11 to 50 people.
Where is Brickell Biotech based?
Brickell Biotech is headquartered in Miami, United States, in the North America region.
Who are Brickell Biotech's main competitors?
Emerging players on record are AnaptysBio and Incyte Corporation. Hologic is listed as an others. Direct peers are Revance Therapeutics, Arcutis Biotherapeutics, Dermavant Sciences, Verrica Pharmaceuticals and Sol-Gel Technologies. Broad incumbents are AbbVie and Galderma.
Does Brickell Biotech have an API?
No public API is recorded for Brickell Biotech.
What industry is Brickell Biotech in?
Brickell Biotech's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.